Nanoparticles-encapsulated polymeric microneedles for transdermal drug delivery

被引：88
作者：
Chen, Minglong [1 ]
Quan, Guilan [2 ]
Sun, Ying [1 ]
Yang, Dan [2 ]
Pan, Xin [1 ]
Wu, Chuanbin [1 ,2 ]
机构：
[1] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Peoples R China
[2] Jinan Univ, Coll Pharm, Guangzhou 510632, Peoples R China
来源：
JOURNAL OF CONTROLLED RELEASE | 2020年 / 325卷
关键词：
Transdermal drug delivery; Polymeric microneedles; Nanoparticles; Controlled drug delivery; Disease therapy;
D O I：
10.1016/j.jconrel.2020.06.039
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Polymeric microneedles (MNs) have been leveraged as a novel transdermal drug delivery platform for effective drug permeation, which were widely used in the treatment of various diseases. However, issues including limited loading capacity of hydrophobic drugs, uncontrollable drug release rates, and monotonic therapeutic strategy hamper the further application of polymeric MNs. As a recent emerging research topic, drawing inspiration from the ways that nanomedicine integrated with MNs have opened new avenues for disease therapy. In this review, we examined the recent studies employing nanoparticles (NPs)-encapsulated polymeric MNs (NPs@MNs) for transdermal delivery of various therapeutic cargos, particularly focused on the application of NPs@MNs for diabetes therapy, infectious disease therapy, cancer therapy, and other dermatological disease therapy. We also provided an overview of the clinical potential and future translation of NPs@MNs.
引用
收藏
页码：163 / 175
页数：13
相关论文
共 161 条
  • [1] Barry B.W., Breaching the skin's barrier to drugs, Nat. Biotechnol., 22, 2, pp. 165-167, (2004)
  • [2] Watkinson A.C., Kearney M.C., Quinn H.L., Courtenay A.J., Donnelly R.F., Future of the transdermal drug delivery market--have we barely touched the surface?, Expert Opin. Drug Deliv., 13, 4, pp. 523-532, (2016)
  • [3] Prausnitz M.R., Langer R., Transdermal drug delivery, Nat. Biotechnol., 26, 11, pp. 1261-1268, (2008)
  • [4] Dragicevic N., Maibach H., Combined use of nanocarriers and physical methods for percutaneous penetration enhancement, Adv. Drug Deliv. Rev., 127, pp. 58-84, (2018)
  • [5] Malinovskaja-Gomez K., Labouta H.I., Schneider M., Hirvonen J., Laaksonen T., Transdermal iontophoresis of flufenamic acid loaded PLGA nanoparticles, Eur. J. Pharm. Sci., 89, pp. 154-162, (2016)
  • [6] Yarmush M.L., Golberg A., Sersa G., Kotnik T., Miklavcic D., Electroporation-based technologies for medicine: principles, applications, and challenges, Annu. Rev. Biomed. Eng., 16, pp. 295-320, (2014)
  • [7] Prausnitz M.R., Mitragotri S., Langer R., Current status and future potential of transdermal drug delivery, Nat. Rev. Drug Discov., 3, 2, pp. 115-124, (2004)
  • [8] Alexander A., Dwivedi S., Ajazuddin T.K.G., Saraf S., Saraf S., Tripathi D.K., Approaches for breaking the barriers of drug permeation through transdermal drug delivery, J. Control Release, 164, 1, pp. 26-40, (2012)
  • [9] Yan L., Yang Y., Zhang W., Chen X., Advanced materials and nanotechnology for drug delivery, Adv. Mater., 26, 31, pp. 5533-5540, (2014)
  • [10] Jin X., Zhu D.D., Chen B.Z., Ashfaq M., Guo X.D., Insulin delivery systems combined with microneedle technology, Adv. Drug Deliv. Rev., 127, pp. 119-137, (2018)
12345678910